Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05206084
Other study ID # IBS II
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 10, 2022
Est. completion date January 2028

Study information

Verified date August 2023
Source Biotyx Medical (Shenzhen) Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective, multi-center, single-blinded, randomized trial to assess the safety and efficacy of the Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS) in treating patients with coronary artery disease compared to the Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System (XIENCE).


Description:

IRONMAN-II is a prospective, multi-center, single-blinded, randomized trial to assess the safety and efficacy of the Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS) in treating patients with coronary artery disease compared to the Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System (XIENCE). A total of 518 subjects with coronary artery lesion(s) are intended to participate in this study. Angiographic follow-up will be required at 2 years, and an OCT subset including 50 subjects will undergo OCT follow-up. Clinical follow-up will be required at postoperative, 1 month, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years. The primary endpoint is late lumen loss at 2 years. The primary objective of this trial is to support the China pre-market approval of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System. IRONMAN-II will evaluate the safety and efficacy of the IBS in treating patients with coronary artery disease. The primary endpoint is late lumen loss at 2 years. The powered secondary objective is to evaluate long-term vascular function and patency of the IBS treated segments compared to XIENCE treated segments. The powered secondary endpoints include Quantitative Flow Ratio (QFR) and cross-section level mean flow area measured by OCT for OCT subset at 2 years. Data from the primary endpoint and two powered secondary endpoints will evaluate the non-inferiority of the IBS as compared to XIENCE.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 518
Est. completion date January 2028
Est. primary completion date February 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Patient must between 18 and 75 years old, male or non-pregnant female. 2. Patient must have evidence of myocardial ischemia (e.g., stable, unstable angina, silent myocardial ischemia, or acute myocardial infarction>1 week) suitable for elective PCI. 3. One or two de novo target lesions each located in a different epicardial vessel. 1. If there is one target lesion, another non-target lesion may be treated but the non-target lesion must be present in a different epicardial vessel, and must be treated first with a successful result prior to randomization of the target lesion. 2. If two target lesions are present, they must be present in different epicardial vessels and both satisfy the angiographic eligibility criteria. 3. The definition of epicardial vessels means the left anterior descending artery (LAD), the left circumflex artery (LCX), and the right coronary artery (RCA) and their branches. Thus, for example, the subject must not have lesions requiring treatment in both the LAD and a diagonal branch. 4. Lesion(s) must have a visually estimated length of =33mm, diameter between range of 2.5-4.0mm, and each lesion can be completely covered by a stent. 5. Lesion(s) must have a visually estimated diameter stenosis of =70% (or =50% and have evidence of myocardial ischemia in this location) with a TIMI flow of =1. 6. Patient can understand the study purpose, voluntarily participate in the study, sign the informed consent, and willing to undergo protocol-required invasive angiographic follow-ups. Exclusion Criteria: - General Exclusion Criteria 1. Patient had an acute myocardial infarction (AMI) or CK and CK-MB have not returned to within normal limits after myocardial infarction within 7 days of the index procedure. 2. Patient has implanted stent in the target vessel within 1 year of the index procedure, or is scheduled to undergo re-intervention in the future 6 months. 3. Patient with a history of coronary artery bypass (coronary artery bypass grafting). 4. Patient with contraindications on coronary artery bypass graft surgery. 5. Patient with severe heart failure (NYHA class =III) or left ventricular ejection fraction<40% (by echocardiography or contrast left ventriculography). 6. Patient with known renal insufficiency: serum creatinine > 2.0 mg/dl or 177 µmol/L, or/and patient on dialysis. 7. Patient with known hepatic insufficiency: ALT, AST >3 times the upper limit of normal. 8. Patient had an ischemic stroke within 6 months or transient ischemic neurological attack (TIA) within 3 months before the index procedure, or has tendency of hypercoagulation as per investigator judgement or laboratory test. 9. Patient with bleeding diathesis, active gastrointestinal ulcers, history of cerebral hemorrhage or subarachnoid hemorrhage, contraindications on antiplatelet agents and anticoagulant therapy, and unable to undergoing antithrombotic therapy. 10. Patient with known allergy to aspirin, clopidogrel, heparin, contrast agent, PDLLA, sirolimus and metal (iron, zinc etc). 11. Patient with a history of disease related to iron overload or iron disorder, such as hereditary hemochromatosis, etc. 12. Patient with life expectancy <2 years. 13. Patient is already participating in another drug or medical device clinical trial that has not yet reached its primary endpoint. 14. Patient with poor compliance and cannot comply with the protocol requirement as per investigator judgement. 15. Subject has received a heart transplant. 16. Patient with unstable arrhythmia, such as high-risk ventricular premature beat and ventricular tachycardia. 17. Patient requires chemotherapy for malignancy. 18. Patient with known immunosuppressive or autoimmune disease, and is receiving or scheduled to receive immunosuppressant therapy. 19. Patient is receiving or scheduled to receive chronic anticoagulation therapy such as aspirin and warfarin, etc. 20. Patient is scheduled to receive a surgery that requires to stop antiplatelet drugs such as heparin and clopidogrel within 6 months after the index procedure. 21. Patient has a platelet count <100x10^9/L or >700 x10^9/L, a white blood cell count of <3 x10^9/L during the screening period. 22. Patient with diffuse peripheral vascular disease, and cannot use 6F catheter. 23. Patient with prior valvular surgery. - Angiographic exclusion criteria 1. Chronic total occlusion (TIMI flow of 0 before the index procedure). 2. Target lesion is located in left main. 3. Aorto-ostial lesion (within 3 mm of the ostium). 4. Target lesion involving a bifurcation lesion with side branch =2.5 mm in diameter (the ostium of side branch has restenosis =40% or require balloon pre-dilatation). 5. Visible thrombus in target vessels. 6. Severe triple vessels lesions and all require revascularization. 7. Severe calcified or distorted lesions which unable to predilate, not suitable for stent delivery and expansion, impair delivery including: 1. Extreme angulation (= 90°) proximal to or within the target lesion 2. Excessive tortuosity (= two 45° angles) proximal to or within the target lesion 3. Moderate or heavy calcification proximal to or within the target lesion 8. In-stent restenosis target lesion. 9. Target lesion involves a myocardial bridge. 10. The investigational stent would need to cross the previously implanted stent to reach the target lesion. 11. Target lesion which prevents complete balloon pre-dilatation, defined as full balloon expansion with the following outcomes: 1. Residual diameter stenosis (DS%) is < 40% (per visual estimation), = 20% is strongly recommended. 2. TIMI flow of 3 (per visual estimation). 3. No angiographic complications (e.g., distal embolization, side branch closure). 4. No dissections National Heart, Lung, and Blood Institute (NHLBI) grade D-F. 5. No chest pain lasting > 5 minutes. 6. No ST depression or elevation lasting > 5 minutes.

Study Design


Intervention

Device:
Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)
Subjects in this arm will be treated with IBS
Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
Subjects in this arm will be treated with XIENCE

Locations

Country Name City State
China Fuwai Yunnan Cardiovascular Hospital Kunming

Sponsors (1)

Lead Sponsor Collaborator
Biotyx Medical (Shenzhen) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary In-segment Late lumen loss (LLL) 2 years
Secondary Powered Secondary Endpoint: Quantitative Flow Ratio (QFR) 2 years
Secondary Powered Secondary Endpoint: Cross-section level mean flow area measured by OCT Only for subjects in OCT subset 2 years
Secondary Rate of Device Success Device Success is defined as: A visually estimated diameter stenosis of < 30% after implantation of the device and TIMI flow of III. Immediately post-procedure
Secondary Rate of Lesion Success Lesion Success is defined as: The attainment of visual residual stenosis < 30% and TIMI flow of III after any intervention in target lesion. Immediately post-procedure
Secondary Rate of Clinical Success Clinical Success is defined as: lesion success, AND there is no major adverse cardiac event in the hospitalization period. = 7 days post the index procedure (In-hospital )
Secondary Rate of Device-oriented Composite Endpoint (DoCE) Target Lesion Failure (TLF), defined as the composited endpoints of cardiac death/Target Vessel Myocardial Infarction (TV-MI)/Ischemic-Driven Target Lesion Revascularization (ID-TLR). 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years
Secondary Rate of Patient-oriented Composite Endpoint (PoCE) Including all-cause mortality, any myocardial infarction and any revascularization. 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years
Secondary Rate of Death (Cardiac, Vascular and Non-cardiovascular) 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years
Secondary Rate of Myocardial infarction (Attributable to target vessel (TV-MI),or Not attributable to target vessel (NTV-MI)) 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years
Secondary Rate of Target Lesion Revascularization (Ischemia driven, or not ischemia driven) 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years
Secondary Rate of Target Vessel Revascularization (Ischemia driven, or not ischemia driven) 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years
Secondary Rate of all coronary revascularization 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years
Secondary Rate of Stent Thrombosis defined by ARC (definite and probable) Stent thrombosis is defined by Academic Research Consortium (ARC) criteria as definite, probable, and possible. Stent thrombosis was categorized as acute, Subacute, late, very late. 1 Month, 6 Months, 1 Year, 2 Years, 3 Years, 4 Years, 5 Years
Secondary Acute recoil Immediately post-procedure
Secondary Minimal lumen diameter (MLD) (In-stent, in-segment, proximal 5mm and distal 5mm MLD) at post-procedure, 2 years
Secondary Diameter stenosis (DS %) (In-device, in-segment, proximal 5mm and distal 5mm DS%) at post-procedure, 2 years
Secondary Late Lumen Loss (LLL) (In-device, proximal 5mm and distal 5mm LLL) 2 years
Secondary Angiographic binary restenosis (ABR) (In-device, in-segment, proximal 5mm and distal 5mm ABR) 2 years
Secondary Thickness of neointima (struts level) 2 years
Secondary Minimal lumen area 2 years
Secondary Percentage of neointima-covered struts 2 years
Secondary Late incomplete strut apposition 2 years
Secondary Lumen area stenosis % 2 years
Secondary Healing score Healing score = (presence of intra-scaffold structure * 4) + (presence of both malapposed and uncovered struts * 3) + (presence of uncovered struts alone * 2) + (presence of malapposition alone * 1). 2 years
Secondary Stent Absorption (%) 2 years
Secondary Late recoil area 2 years
Secondary Late recoil proportion 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Coronary De Novo Lesions N/A